Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye

Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye

For Myriad Genetics, Foundation Medicine and other manufacturers of next-generation sequencing (NGS)-based test panels for early-stage cancer risk assessment, the recent announcement of CMS’ decision to provide limited Medicare coverage

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here